Royal Bank of Canada
AVXL icon

Royal Bank of Canada’s Anavex Life Sciences AVXL Stock Holding History

Royal Bank of Canada’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15K Sell
4,727
-10,758
-69% -$46.6K ﹤0.01% 6006
2025
Q4 		$56K Buy
15,485
+1,081
+8% +$6.62K ﹤0.01% 5493
2025
Q3 		$129K Sell
14,404
-8,823
-38% -$89.5K ﹤0.01% 5359
2025
Q2 		$214K Buy
23,227
+2,283
+11% +$19.5K ﹤0.01% 5106
2025
Q1 		$179K Sell
20,944
-4,215
-17% -$39.8K ﹤0.01% 4781
2024
Q4 		$269K Buy
25,159
+8,423
+50% +$64.8K ﹤0.01% 4565
2024
Q3 		$95K Buy
16,736
+74
+0.4% +$427 ﹤0.01% 5377
2024
Q2 		$70K Sell
16,662
-71
-0.4% -$287 ﹤0.01% 5482
2024
Q1 		$86K Sell
16,733
-20,079
-55% -$113K ﹤0.01% 5261
2023
Q4 		$343K Buy
36,812
+13,603
+59% +$93.6K ﹤0.01% 4607
2023
Q3 		$151K Buy
23,209
+2,644
+13% +$21K ﹤0.01% 5052
2023
Q2 		$167K Buy
20,565
+1,930
+10% +$16.5K ﹤0.01% 4915
2023
Q1 		$159K Sell
18,635
-6,178
-25% -$61.7K ﹤0.01% 4810
2022
Q4 		$230K Buy
24,813
+10,400
+72% +$111K ﹤0.01% 4759
2022
Q3 		$149K Buy
14,413
+458
+3% +$4.83K ﹤0.01% 5000
2022
Q2 		$140K Sell
13,955
-3,679
-21% -$34.8K ﹤0.01% 5080
2022
Q1 		$218K Sell
17,634
-9,728
-36% -$120K ﹤0.01% 5004
2021
Q4 		$475K Buy
27,362
+11,265
+70% +$214K ﹤0.01% 4507
2021
Q3 		$289K Buy
16,097
+3,609
+29% +$71.8K ﹤0.01% 4813
2021
Q2 		$286K Buy
12,488
+2,346
+23% +$34.7K ﹤0.01% 4757
2021
Q1 		$151K Buy
10,142
+2,036
+25% +$22.2K ﹤0.01% 5149
2020
Q4 		$45K Buy
8,106
+302
+4% +$1.59K ﹤0.01% 5702
2020
Q3 		$36K Buy
7,804
+6,857
+724% +$29.5K ﹤0.01% 5479
2020
Q2 		$4K Sell
947
-160
-14% -$605 ﹤0.01% 6088
2020
Q1 		$3K Sell
1,107
-1,149
-51% -$4K ﹤0.01% 6169
2019
Q4 		$6K Buy
2,256
+1,847
+452% +$4.85K ﹤0.01% 6285
2019
Q3 		$1K Sell
409
-244
-37% -$704 ﹤0.01% 6402
2019
Q2 		$2K Buy
653
+253
+63% +$786 ﹤0.01% 6551
2019
Q1 		$1K Hold
400
– – ﹤0.01% 6612
2018
Q4 		$1K Sell
400
-12
-3% -$27 ﹤0.01% 6544
2018
Q3 		$1K Hold
412
– – ﹤0.01% 6583
2018
Q2 		$1K Sell
412
-18
-4% -$50 ﹤0.01% 6331
2018
Q1 		$1K Sell
430
-597
-58% -$1.69K ﹤0.01% 6183
2017
Q4 		$3K Sell
1,027
-3,126
-75% -$12.3K ﹤0.01% 6183
2017
Q3 		$18K Buy
4,153
+3,163
+319% +$14.1K ﹤0.01% 5997
2017
Q2 		$5K Sell
990
-742
-43% -$4.29K ﹤0.01% 6030
2017
Q1 		$10K Sell
1,732
-898
-34% -$4.64K ﹤0.01% 5957
2016
Q4 		$11K Buy
2,630
+2,208
+523% +$7.87K ﹤0.01% 6041
2016
Q3 		$1K Buy
422
+22
+6% +$93 ﹤0.01% 6260
2016
Q2 		$2K Hold
400
– – ﹤0.01% 6132
2016
Q1 		$2K Hold
400
– – ﹤0.01% 6115
2015
Q4 		$2K Buy
+400
New +$2.85K ﹤0.01% 6349

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Royal Bank of Canada's AVXL Position: Q1 2026 in Review

Royal Bank of Canada reduced its Anavex Life Sciences (AVXL) stake by 69% in Q1 2026, selling an estimated $46.6K and leaving 4,727 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #6006.

Royal Bank of Canada first reported a position in AVXL in Q4 2015 and has held it in 42 quarters since. The position peaked at $475K in Q4 2021. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

  • Royal Bank of Canada held 4,727 shares of Anavex Life Sciences worth $15K as of Q1 2026.
  • Royal Bank of Canada sold 10,758 Anavex Life Sciences shares in Q1 2026, an estimated $46.6K.
  • Anavex Life Sciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6006 holding.
  • Royal Bank of Canada first reported a position in Anavex Life Sciences in Q4 2015 and has held it in 42 quarters since.
  • Royal Bank of Canada's Anavex Life Sciences position peaked at $475K in Q4 2021.
  • 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.